DAGOBERTO CALLEGARO

(Fonte: Lattes)
Índice h a partir de 2011
20
Lattes
ResearcherID
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/45 - Laboratório de Fisiopatologia Neurocirúrgica, Hospital das Clínicas, Faculdade de Medicina
LIM/62 - Laboratório de Fisiopatologia Cirúrgica, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Autor e Coautores FMUSP-HC Normalizados: RENATA FARIA SIMM × Autor e Coautores FMUSP-HC Normalizados: SAMIRA LUISA DOS APOSTOLOS PEREIRA × search.filters.applied.f.dateIssued: 2015 ×

Resultados de Busca

Agora exibindo 1 - 4 de 4
  • conferenceObject
    Clinically suspected neuromyelitis optica associated to anti-MOG antibodies
    (2015) SALLES, L. M. O. de Paula; SATO, D. K.; APOATOLOS-PEREIRA, S. L.; SIMM, R. F.; JORGE, F. M. H.; FUJIHARA, K.; CALLEGARO, D.
  • conferenceObject
    Cerebrospinal Fluid Aquaporin-4 Antibody Levels in Neuromyelitis Optica Attacks
    (2015) SATO, D. K.; CALLEGARO, D.; JORGE, F. M. H.; NAKASHIMA, I.; NISHIYAMA, S.; TAKAHASHI, T.; SIMM, R. F.; APOSTOLOS-PEREIRA, S. L.; MISU, T.; STEINMAN, L.; AOKI, M.; FUJIHARA, K.
  • conferenceObject
    Autoantibodies against MOG in Neuromyelitis Optica Spectrum Disorders
    (2015) SATO, D. K.; CALLEGARO, D.; LANA-PEIXOTO, M. A.; WATERS, P. J.; TANAKA, S.; JORGE, F.; TAKAHASHI, T.; MISU, T.; APOSTOLOS-PEREIRA, S. L.; TALIM, N.; SIMM, R. F.; LINO, A. M. M.; NAKASHIMA, I.; NOMURA, K.; AOKI, M.; FUJIHARA, K.
  • article 5 Citação(ões) na Scopus
    Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers
    (2015) OLIVEIRA, Enedina Maria Lobato de; SIMM, Renata Faria; DASIC, Gorana; MORAIS, Marilia Mamprim de; PERREIRA, Samira Luiza dos Apostolos; CALLEGARO, Dagoberto
    Objective: Analyze the demographics, clinical characteristics, efficacy and safety of natalizumab treatment in Brazilian patients with multiple sclerosis (MS) followed up for at least 12 months, in two tertiary MS care centers in Sao Paulo. Method: We evaluated the effect of natalizumab treatment on annualized relapse rate and disability progression in 75 patients with MS treated with natalizumab for at least 12 months. A subgroup analysis was performed to evaluate efficacy of natalizumab treatment in patients with Expanded Disability Status Scale (EDSS) <= 3.0 vs patients with EDSS > 3. Results: Patients treated for at least one year with natalizumab showed a 91% reduction in aRR, as well and an improvement in neurological disability. The impact of natalizumab treatment was greater in patients with EDSS < 3.0. Overall, natalizumab was safe but one patient developed progressive multifocal leukoencephalopathy. Conclusion: Natalizumab as a third line therapy is safe and efficacious, especially in patients with mild neurological disability.